EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open‐Label, Multicenter Phase 2 Study

Shuang Huang, Ya-Qian Han, Kun-Yu Yang, Song Qu, Shen-Hong Qu, Meng-Yun Qiang, Cai-Neng Cao, Xiao-Zhong Chen iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70542 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Shuang Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Radiotherapy, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Nasopharyngeal Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Medical and Health Research Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This prospective exploratory phase 2 study employed a three‐cohort, two‐phase design to evaluate the potential of anlotinib as a substitute for cisplatin in gemcitabine–penpulimab combinations for metastatic nasopharyngeal carcinoma (NPC) patients who were previously treated with cisplatin‐based chemoradiotherapy. Patients enrolled in the study were randomized in a 1:1:1 ratio during the lead‐in phase to one of three treatment arms: gemcitabine, cisplatin, penpulimab, and anlotinib (GP‐PA, n = 8); gemcitabine, cisplatin, and penpulimab (GP‐P, n = 6); or gemcitabine, penpulimab, and anlotinib (GAP, n = 6). The expansion phase enriched the optimal cohort, with stratification based on PD‐L1 expression. The primary endpoints were safety and objective response rate (ORR), while the secondary endpoints included duration of response, disease control rate (DCR), progression‐free survival (PFS), and overall survival (OS). In the lead‐in phase, grade ≥ 3 treatment‐emergent adverse events (TEAEs) occurred in 87.5% (GP‐PA), 100% (GP‐P), and 66.7% (GAP) patients, predominantly hematologic toxicities. ORR/DCR were 62.5%/87.5% (GP‐PA), 83.3%/100% (GP‐P), and 100%/100% (GAP). At median 20.2‐month follow‐up, median PFS/OS were 4.1/18.4 months for GP‐PA and not reached for GP‐P/GAP. In the expansion phase, a total of 14 patients received GAP, with an ORR of 93.3% and grade ≥ 3 TEAEs in 71.4% of patients. At data cut‐off point, the median PFS had not been reached, and the 12‐month PFS and OS rates were 53.8% and 78.6%, respectively. The GAP regimen demonstrated a favorable safety and efficacy profile, compared to the GP‐PA and GP‐P regimens in patients with metastatic NPC. These findings suggest that substituting cisplatin with anlotinib may offer a viable therapeutic strategy for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaDeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsNasopharyngeal NeoplasmsHumansGemcitabineQuinolinesIndolesFemaleMiddle AgedMaleAdultAgedProspective StudiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

anlotinibfirst‐linegemcitabinenasopharyngeal carcinomapenpulimab

Substanzen

GemcitabineDeoxycytidineanlotinibQuinolinesIndolespenpulimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Head and Neck Radiotherapy, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China.
  • Department of Radiotherapy, Hunan Cancer Hospital, Changsha, Hunan, China.
  • Department of Radiotherapy, Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
  • Department of Radiotherapy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
  • Department of Radiotherapy, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China.

ORCID-Profile: Xiao-Zhong Chen

Förderung

  • the Medical and Health Research Project of Zhejiang Province

Zitieren

APA

Huang, S., Han, Y. Q., Yang, K. Y., Qu, S., Qu, S. H., Qiang, M. Y., Cao, C. N., & Chen, X. Z. (2026). Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open‐Label, Multicenter Phase 2 Study. International Journal of Cancer. https://doi.org/10.1002/ijc.70542

Vancouver

Huang S, Han YQ, Yang KY, Qu S, Qu SH, Qiang MY, et al. Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open‐Label, Multicenter Phase 2 Study. International Journal of Cancer. 2026. doi:10.1002/ijc.70542

BibTeX
@article{Huang2026,
  author = {Huang, Shuang and Han, Ya-Qian and Yang, Kun-Yu and Qu, Song and Qu, Shen-Hong and Qiang, Meng-Yun and Cao, Cai-Neng and Chen, Xiao-Zhong},
  title = {Penpulimab and Gemcitabine With or Without Anlotinib in Metastatic Nasopharyngeal Carcinoma: A Randomized, Open‐Label, Multicenter Phase 2 Study},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70542}
}
Kostenlos starten →